B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation

Rachel M. Gibbons, Xin Liu, Susan M. Harrington, Christopher J. Krco, Eugene D Kwon, Haidong M Dong

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A promising strategy in tumor immunotherapy is the use of activated dendritic cells as vehicles for tumor vaccines with the goal of activating anti-tumor T cell responses. Current formulations for dendritic cell-based immunotherapies have limited effects on patient survival, providing motivation for further investigation of ways to enhance dendritic cell priming of anti-tumor T cell responses. Using a brief in vitro priming model, we have found that B7-H1 expressed by activated dendritic cells is integrated during priming of naïve CD8+ T cells and functions to limit the differentiation of effector T cell responses. CD8+ T cells primed by B7-H1-deficient dendritic cells exhibit increased production of IFN-γ, enhanced target cell killing, and improved anti-tumor activity. Additionally, enhanced memory populations arise from CD8+ T cells primed by B7-H1-deficient dendritic cells. Based on these findings, we suggest that early blockade of B7-H1 signaling should be investigated as a strategy to improve dendritic cell-based anti-tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)859-867
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume63
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Dendritic Cells
T-Lymphocytes
Immunotherapy
Neoplasms
Cancer Vaccines
Motivation
Survival
Population

Keywords

  • Co-stimulatory signaling
  • T cell priming

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation. / Gibbons, Rachel M.; Liu, Xin; Harrington, Susan M.; Krco, Christopher J.; Kwon, Eugene D; Dong, Haidong M.

In: Cancer Immunology, Immunotherapy, Vol. 63, No. 8, 2014, p. 859-867.

Research output: Contribution to journalArticle

Gibbons, Rachel M. ; Liu, Xin ; Harrington, Susan M. ; Krco, Christopher J. ; Kwon, Eugene D ; Dong, Haidong M. / B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation. In: Cancer Immunology, Immunotherapy. 2014 ; Vol. 63, No. 8. pp. 859-867.
@article{4b1a58fbc9054b5698a5726e50e844c9,
title = "B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation",
abstract = "A promising strategy in tumor immunotherapy is the use of activated dendritic cells as vehicles for tumor vaccines with the goal of activating anti-tumor T cell responses. Current formulations for dendritic cell-based immunotherapies have limited effects on patient survival, providing motivation for further investigation of ways to enhance dendritic cell priming of anti-tumor T cell responses. Using a brief in vitro priming model, we have found that B7-H1 expressed by activated dendritic cells is integrated during priming of na{\"i}ve CD8+ T cells and functions to limit the differentiation of effector T cell responses. CD8+ T cells primed by B7-H1-deficient dendritic cells exhibit increased production of IFN-γ, enhanced target cell killing, and improved anti-tumor activity. Additionally, enhanced memory populations arise from CD8+ T cells primed by B7-H1-deficient dendritic cells. Based on these findings, we suggest that early blockade of B7-H1 signaling should be investigated as a strategy to improve dendritic cell-based anti-tumor immunotherapy.",
keywords = "Co-stimulatory signaling, T cell priming",
author = "Gibbons, {Rachel M.} and Xin Liu and Harrington, {Susan M.} and Krco, {Christopher J.} and Kwon, {Eugene D} and Dong, {Haidong M}",
year = "2014",
doi = "10.1007/s00262-014-1563-6",
language = "English (US)",
volume = "63",
pages = "859--867",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation

AU - Gibbons, Rachel M.

AU - Liu, Xin

AU - Harrington, Susan M.

AU - Krco, Christopher J.

AU - Kwon, Eugene D

AU - Dong, Haidong M

PY - 2014

Y1 - 2014

N2 - A promising strategy in tumor immunotherapy is the use of activated dendritic cells as vehicles for tumor vaccines with the goal of activating anti-tumor T cell responses. Current formulations for dendritic cell-based immunotherapies have limited effects on patient survival, providing motivation for further investigation of ways to enhance dendritic cell priming of anti-tumor T cell responses. Using a brief in vitro priming model, we have found that B7-H1 expressed by activated dendritic cells is integrated during priming of naïve CD8+ T cells and functions to limit the differentiation of effector T cell responses. CD8+ T cells primed by B7-H1-deficient dendritic cells exhibit increased production of IFN-γ, enhanced target cell killing, and improved anti-tumor activity. Additionally, enhanced memory populations arise from CD8+ T cells primed by B7-H1-deficient dendritic cells. Based on these findings, we suggest that early blockade of B7-H1 signaling should be investigated as a strategy to improve dendritic cell-based anti-tumor immunotherapy.

AB - A promising strategy in tumor immunotherapy is the use of activated dendritic cells as vehicles for tumor vaccines with the goal of activating anti-tumor T cell responses. Current formulations for dendritic cell-based immunotherapies have limited effects on patient survival, providing motivation for further investigation of ways to enhance dendritic cell priming of anti-tumor T cell responses. Using a brief in vitro priming model, we have found that B7-H1 expressed by activated dendritic cells is integrated during priming of naïve CD8+ T cells and functions to limit the differentiation of effector T cell responses. CD8+ T cells primed by B7-H1-deficient dendritic cells exhibit increased production of IFN-γ, enhanced target cell killing, and improved anti-tumor activity. Additionally, enhanced memory populations arise from CD8+ T cells primed by B7-H1-deficient dendritic cells. Based on these findings, we suggest that early blockade of B7-H1 signaling should be investigated as a strategy to improve dendritic cell-based anti-tumor immunotherapy.

KW - Co-stimulatory signaling

KW - T cell priming

UR - http://www.scopus.com/inward/record.url?scp=84906791210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906791210&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1563-6

DO - 10.1007/s00262-014-1563-6

M3 - Article

C2 - 24893858

AN - SCOPUS:84906791210

VL - 63

SP - 859

EP - 867

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -